ASAnantha Shekhar

Anantha Shekhar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anantha Shekhar has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Andrei I. Molosh

    Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, USA

    6 shared publications
  • Phillip L. Johnson

    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN 46202, USA

    4 shared publications
  • E. T. Dustrude

    Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA

    2 shared publications
  • Erik T. Dustrude

    Department of Psychiatry, Paul and Carole Stark Neurosciences Research Institute, Indiana Clinical and Translational Sciences Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202

    2 shared publications
  • Jodi L. Lukkes

    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States

    2 shared publications
  • S. D. Fitz

    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA

    2 shared publications

Latest Publications

  • Open Access

    Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities

    by Michael J. Pugia, Meeta Pradhan, Rong Qi, Doreen L. Eastes, Anna Geisinger, Bradley J. Mills, Zane Baird, Aruna Wijeratne, Scott M. McAhren, Amber L. Mosley, et al.

    BACKGROUND: Diabetes is a complex, multi-symptomatic disease that drives healthcare costs through its complications as the prevalence of this disease grows rapidly world-wide. Real-world electronic health records (EHRs) coupled with patient biospecimens, biological understanding, and technologies can lead to identification of new diagnostic markers. METHODS: We analyzed the 20-year EHRs of 1862 participants with midpoint samples (10-year) in an observational study of type 2 diabetes and cardiovascular arterial disease (CVAD) conducted by the Fairbanks Institute to test the diagnostic biomarkers. Participants were assigned to four cohorts (healthy, diabetes, CVAD, CVAD+diabetes) based on EHR data analysis. The immunoassay reference range for circulating autoantibodies against the C-terminal fragment of adiponectin receptor 1 (IgG-CTF) was determined and used to predict outcomes post-sample. RESULTS: The IgG-CTF reference range was determined [75–821 ng/mL] and out-of-range values of IgG-CTF values predicted increased likelihood of additional comorbidities and mortality determined from the EHRs 10 years after sample collection. The probability of mortality was lower in patients with elevated IgG-CTF >821 ng/mL [OR 0.49–0.0] and higher in patients with lowered IgG-CTF <75 ng/mL [OR 3.74–9.64]. Although many patients at the time of sample collection had other conditions (hypertension, hyperlipidemia, or elevated uristatin values), only hypertension correlated with increased likelihood of mortality (OR 4.36–5.34). CONCLUSIONS: This study confirms that retrospective analysis of biorepositories coupled with EHRs can provide insight into novel diagnostic markers and the IgG-CTF marker can predict the likelihood of progressing to additional comorbidities or mortality.

  • Open Access

    The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents

    by Yu Xu, Lucas Cantwell, Andrei I. Molosh, Leigh D. Plant, Dimitris Gazgalis, Stephanie D. Fitz, Erik T. Dustrude, Yuchen Yang, Takeharu Kawano, Sumanta Garai, et al.


  • Open Access

    Orexin Depolarizes Central Amygdala Neurons via Orexin Receptor 1, Phospholipase C and Sodium-Calcium Exchanger and Modulates Conditioned Fear

    by Erik T. Dustrude, Izabela F. Caliman, Cristian S. Bernabe, Stephanie D. Fitz, Laura A. Grafe, Seema Bhatnagar, Pascal Bonaventure, Philip L. Johnson, Andrei I. Molosh, Anantha Shekhar

    Orexins (OX), also known as hypocretins, are excitatory neuropeptides with well-described roles in regulation of wakefulness, arousal, energy homeostasis, and anxiety. An additional and recently recognized role of OX is modulation of fear responses. We studied the OX neurons of the perifornical hypothalamus (PeF) which send projections to the amygdala, a region critical in fear learning and fear expression. Within the amygdala, the highest density of OX-positive fibers was detected in the central nucleus (CeA). The specific mechanisms underlying OX neurotransmission within the CeA were explored utilizing rat brain slice electrophysiology, pharmacology, and chemogenetic stimulation. We show that OX induces postsynaptic depolarization of medial CeA neurons that is mediated by OX receptor 1 (OXR1) but not OX receptor 2 (OXR2). We further characterized the mechanism of CeA depolarization by OX as phospholipase C (PLC)- and sodium-calcium exchanger (NCX)- dependent. Selective chemogenetic stimulation of OX PeF fibers recapitulated OXR1 dependent depolarization of CeA neurons. We also observed that OXR1 activity modified presynaptic release of glutamate within the CeA. Finally, either systemic or intra-CeA perfusion of OXR1 antagonist reduced the expression of conditioned fear. Together, these data suggest the PeF-CeA orexinergic pathway can modulate conditioned fear through a signal transduction mechanism involving PLC and NCX activity and that selective OXR1 antagonism may be a putative treatment for fear-related disorders.


  • Role of medial hypothalamic orexin system in panic, phobia and hypertension

    by Aline R. Abreu, Andrei I. Molosh, Philip L. Johnson, Anantha Shekhar


  • Open Access

    PSD95 and nNOS interaction as a novel molecular target to modulate conditioned fear: relevance to PTSD

    by L.- P. Li, E. T. Dustrude, M. M. Haulcomb, A. R. Abreu, S. D. Fitz, P. L. Johnson, G. A. Thakur, A. I. Molosh, Y. Lai, A. Shekhar

    Stimulation of N-methyl-D-aspartic acid receptors (NMDARs) and the resulting increase of nitric oxide (NO) production are critical for fear memory formation. Following NMDAR activation, efficient production of NO requires linking the 95 kDa postsynaptic density protein (PSD95), a scaffolding protein to neuronal nitric oxide synthase (nNOS). A variety of previously studied NMDAR antagonists and NOS inhibitors can disrupt fear conditioning, but they also affect many other CNS functions such as motor activity, anxiety, and learning. We hypothesized that disrupting nNOS and PSD95 interaction in the amygdala, a critical site for fear memory formation, will reduce conditioned fear. Our results show that systemic treatment with ZL006, a compound that disrupts PSD95/nNOS binding, attenuates fear memory compared to its inactive isomer ZL007. Co-immunoprecipitation after fear conditioning showed a robust increase in the amygdala PSD95/nNOS binding, which was blocked by systemic pre-administration of ZL006. Treatment of amygdala slices with ZL006 also impaired long-term potentiation (LTP), a cellular signature of synaptic plasticity. Direct intra-amygdala infusion of ZL006 also attenuated conditioned fear. Finally, unlike NMDAR antagonist MK-801, ZL006 does not affect locomotion, social interaction, object recognition memory, and spatial memory. These findings support the hypothesis that disrupting the PSD95/nNOS interaction downstream of NMDARs selectively reduces fear memory, and highlights PSD95/nNOS interaction as a novel target for fear-related disorders, such as posttraumatic stress disorder.


  • Panic results in unique molecular and network changes in the amygdala that facilitate fear responses

    by A. I. Molosh, E. T. Dustrude, J. L. Lukkes, S. D. Fitz, I. F. Caliman, A. R. R. Abreu, A. D. Dietrich, W. A. Truitt, L. Ver Donck, M. Ceusters, et al.

    Recurrent panic attacks (PAs) are a common feature of panic disorder (PD) and post-traumatic stress disorder (PTSD). Several distinct brain regions are involved in the regulation of panic responses, such as perifornical hypothalamus (PeF), periaqueductal gray, amygdala and frontal cortex. We have previously shown that inhibition of GABA synthesis in the PeF produces panic-vulnerable rats. Here, we investigate the mechanisms by which a panic-vulnerable state could lead to persistent fear. We first show that optogenetic activation of glutamatergic terminals from the PeF to the basolateral amygdala (BLA) enhanced the acquisition, delayed the extinction and induced the persistence of fear responses 3 weeks later, confirming a functional PeF-amygdala pathway involved in fear learning. Similar to optogenetic activation of PeF, panic-prone rats also exhibited delayed extinction. Next, we demonstrate that panic-prone rats had altered inhibitory and enhanced excitatory synaptic transmission of the principal neurons, and reduced protein levels of metabotropic glutamate type 2 receptor (mGluR2) in the BLA. Application of an mGluR2-positive allosteric modulator (PAM) reduced glutamate neurotransmission in the BLA slices from panic-prone rats. Treating panic-prone rats with mGluR2 PAM blocked sodium lactate (NaLac)-induced panic responses and normalized fear extinction deficits. Finally, in a subset of patients with comorbid PD, treatment with mGluR2 PAM resulted in complete remission of panic symptoms. These data demonstrate that a panic-prone state leads to specific reduction in mGluR2 function within the amygdala network and facilitates fear, and mGluR2 PAMs could be a targeted treatment for panic symptoms in PD and PTSD patients.


  • From bedside to bench and back: Translating ASD models

    by Hayley P. Drozd, Sotirios F. Karathanasis, Andrei I. Molosh, Jodi L. Lukkes, D. Wade Clapp, Anantha Shekhar


  • Overview of genetic models of autism spectrum disorders

    by Jheel Patel, Jodi L. Lukkes, Anantha Shekhar